Oryzon Genomics Sa Stock Cash And Equivalents

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

In accordance with the recently published financial statements, Oryzon Genomics SA has 29.11 M in Cash And Equivalents. This is 96.45% lower than that of the Biotechnology sector and 93.49% lower than that of the Health Care industry. The cash and equivalents for all Spain stocks is 98.92% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Oryzon Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oryzon Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oryzon Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.